Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Rectal Neoplasms 1Endometrial Neoplasms 1Advanced Solid Tumors 1

Interventions

Leucovorin 38Fluorouracil 36Oxaliplatin 34Bevacizumab 34Irinotecan 32Cetuximab 23Capecitabine 18Panitumumab 14IFL protocol 7Folfox protocol 6Celecoxib 6Radiotherapy 5Nivolumab 5Magnetic Resonance Spectroscopy 5Immunohistochemistry 5Gene Expression Profiling 5regorafenib 4pembrolizumab 4dehydroftorafur 4Ramucirumab 4Fluorodeoxyglucose F18 4Floxuridine 4aflibercept 3Surgical Procedures, Operative 3Sorafenib 3Radiosurgery 3Ipilimumab 3Gemcitabine 3Fentanyl 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Colonic Neoplasms × HMPL-013 × Clear all
NCT04322539 2025-04-04

FRESCO-2

Hutchmed

Phase 3 Completed
691 enrolled 26 charts 1 FDA
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT03251378 2024-09-25

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

Hutchmed

Phase 1 Completed
129 enrolled 32 charts
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡